Updated

Updated · The Conversation · Jun 8

Brain Inflammation Therapy Raises HIV Levels by Cutting Killer T Cells in 40 Million-Person Disease

Updated

Updated · The Conversation · Jun 8

Brain Inflammation Therapy Raises HIV Levels by Cutting Killer T Cells in 40 Million-Person Disease

Q: Why did blocking an immune 'gatekeeper' protein unexpectedly worsen HIV's impact on the brain?

Blocking the α4 integrin worsened HIV’s impact on the brain because it shut out too many of the wrong immune cells. The treatment was meant to stop infected immune cells from entering the central nervous system and fueling inflammation. Instead, the study found that the virus-carrying CD4 “helper” T cells could still get into the brain without relying on α4 integrin. The cells that did depend on α4 integrin were activated CD8 “killer” T cells, which are needed to find and destroy infected cells. When researchers used an integrin-blocking drug already used in multiple sclerosis, those protective CD8 cells were reduced in the brain. That left fewer defenses against infected CD4 cells that continued to seed the virus there. The result was a higher viral load in some brain regions and persistent inflammation, not less. The finding was seen in SIV-infected rhesus macaques and confirmed in engineered mice, strengthening the evidence that the effect was real and not a one-off result. The broader lesson is that immune trafficking in the brain is more selective than researchers assumed. A broad blockade of an immune “gatekeeper” can backfire if harmful cells and protective cells use different routes to enter the brain. For HIV-related brain disease, the study suggests future therapies will need to target specific cell types with much greater precision rather than broadly blocking immune-cell entry.

3 articles · Updated · The Conversation · Jun 8

A study in SIV-infected rhesus macaques found that blocking the alpha-4 integrin to curb brain inflammation increased viral levels in some brain regions instead of lowering them.
The treatment did not keep HIV-carrying helper T cells out of the brain, but it reduced killer T cells that destroy infected cells, leaving more virus and persistent inflammation.
Brain-cell analyses and hippocampus tests showed higher viral levels in helper T cells after treatment and weaker killer T-cell communication with key immune cells.
Mouse experiments backed the mechanism: helper T cells could still enter the brain without alpha-4 integrin, while activated killer T cells depended on it.
The findings suggest HIV brain therapies need more precise immune targeting; more than 40 million people were living with HIV in 2024, and over 22% lacked treatment access.

Sources

The Conversation20h ago

HIV Brain Inflammation Therapy Increases Virus Levels by Reducing Killer T Cells

Beaumont Enterprise20h ago

HIV enters the brain and doesn't leave – paradoxically, drugs intended to reduce brain inflammation increase virus levels

NDTV20h ago

HIV Enters The Brain And Doesn't Leave - Paradoxically, Drugs Intended To Reduce Brain Inflammation Increase Virus Levels

Can new AI-driven immune maps prevent future HIV treatments from backfiring in the brain?

Why did blocking an immune 'gatekeeper' protein unexpectedly worsen HIV's impact on the brain?

Paradoxical Effects of Brain Inflammation Therapies: Rising HIV Brain Levels and the Need for Precision Medicine

Overview

A recent study revealed that brain inflammation therapies for people with HIV, which were designed to reduce harmful neuroinflammation by targeting alpha-4 integrin, had an unexpected effect. Instead of lowering inflammation or HIV levels in the brain, these therapies actually increased HIV levels. This happened because the treatment unintentionally reduced killer T cells, which are crucial for fighting virus-infected cells. As a result, the brain’s ability to control HIV was weakened, leading to more inflammation. This finding highlights the need for precise therapies that support the immune system without causing further harm.

...